
1 Changes in monocyte subsets can predict the risk of AAA and are surrogate markers 2 for AAA morphology in patients with late-stage disease 3 **Short title:** AAA, monocyte subsets, risk prediction, surrogate marker Bianca Hamann<sup>1</sup>, Anna Klimova<sup>2</sup>, Marvin Kapalla<sup>1</sup>, David M. Poitz<sup>3</sup>, Frieda Frank<sup>1</sup>, 4 Henning Morawietz<sup>4</sup>, Christian Reeps<sup>1\*</sup> and Anja Hofmann<sup>1\*</sup> 5 \*contributed equally 6 7 <sup>1</sup>Division of Vascular and Endovascular Surgery, Department of Visceral, Thoracic and 8 Vascular Surgery, University Hospital and Medical Faculty Carl Gustav Carus, TUD Dresden 9 University of Technology, Germany; <sup>2</sup>Institute for Medical Informatics and Biometry, Faculty of Medicine, TUD Dresden 10 11 University of Technology, Germany; 12 <sup>3</sup>Institute for Clinical Chemistry and Laboratory Medicine; University Hospital and Medical 13 Faculty Carl Gustav Carus, TUD Dresden University of Technology, Germany; 14 <sup>4</sup>Division of Vascular Endothelium and Microcirculation, Department of Medicine III, 15 University Hospital and Medical Faculty Carl Gustav Carus, TUD Dresden University of 16 Technology, Germany; 17 **#Corresponding author:** 18 Anja Hofmann, PhD 19 Division of Vascular and Endovascular Surgery 20 Department of Visceral-, Thoracic and Vascular Surgery 21 Faculty of Medicine and University Hospital Carl Gustav Carus 22 TUD Dresden University of Technology 23 Fetscherstraße 74 24 D-01307 Dresden, Germany 25 Email: anja.hofmann2@uniklinikum-dresden.de 26 27 Word count: 3.343 (Excluding references, figure legends and table legends) 28 Word count abstract: 217 29 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# **Graphical Abstract**



**Primary endpoint** Phenotyping of monocyte subsets

Findings						
	Classical monocytes CD14 <sup>++</sup> /CD16 <sup>-</sup>	Intermediate monocytes CD14 <sup>++</sup> /CD16 <sup>+</sup>	Non-classical monocytes CD14+/CD16++			
Count in peripheral blood	Ţ	Ť	<b>†</b>			
AAA risk	<b>↑</b>	<b>↑</b>	<b>↑</b>			
AAA diameter	-	-	inverse			
AAA volume	e –	-	inverse			
Intralumina Thrombus		postive	_			

**Abstract** 

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

**Background** Monocytes play a pivotal role in pathology of abdominal aortic aneurysm (AAA) and can display an immunophenotypic heterogeneity with functionally distinct subpopulations. Alterations in monocyte subsets have been described in CVD, and some are associated with cardiovascular risk, but their profile in AAA is poorly understood. Aim We aimed to comprehensively define associations of circulating monocyte phenotypes with AAA risk and AAA morphology. **Methods** Monocyte subsets (CD14++CD16-; CD14++/CD16+; CD14+/CD16++) were analyzed in a prospective, observational study in patients with AAA (n=34) and varicose veins (n=34) by using flow cytometry. **Results** Classical monocytes were 1.6-fold lower (P=0.001) in AAA, while intermediate and non-classical monocytes were 1.8 (P=0.019) and 1.9-fold (P=0.025) higher in AAA, respectively. The differences remained significant after adjusting for age, sex and peripheral artery disease. A lower proportion of classical monocytes (HR: 0.73, P=0.002) and increases in intermediate (HR: 1.41, P=0.006) and non-classical monocytes (HR: 1.54, P=0.030) were associated with a higher risk of AAA. Non-classical monocytes showed an inverse correlation with AAA diameter (Pearson correlation =-0.64, P=0.001) and AAA volume (Pearson correlation =-0.50, P=0.003). Conclusion The present study revealed age- and sex-independent shifts in monocytes, all of which were associated with risk of AAA disease. Non-classical monocytes were inversely correlated with AAA diameter and volume and thus may be surrogate markers for AAA morphology.

Non-standard abbreviations and acronyms

AAA, abdominal aortic aneurysm; ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CAD, coronary artery disease; CAS, carotid artery stenosis; CCB, calcium channel blocker; CVD, cardiovascular disease; Hb, hemoglobin; HDL, high-density lipoprotein cholesterol; HF, heart failure; LDL,

low-density lipoprotein cholesterol; **PAD**, peripheral artery disease; **T2D**, Type 2 diabetes

61 mellitus; TC, total cholesterol

55

56

57

58

59

What's new?

62

63

72

73

74

75

76

- Classical monocytes are lower in patients with late-stage AAA.
- Non-classical monocytes showed the strongest increase in AAA disease.
- A reduction in classical monocytes is associated with increased risk of AAA.
- An increase in non-classical and intermediate monocytes is associated with an increased
- 67 risk of AAA.
- Lowering in non-classical monocytes may be a surrogate marker for AAA morphology,
- 69 particlarly AAA volume.
- Intermediate monocytes showed a positive correlation with the thickness of the
- 71 intraluminal thrombus.

### What are the clinical implications?

- The increase in non-classical monocytes could be a novel surrogate marker for AAA volume, which could be useful when AAA diameter is insufficient or to monitor a saccular AAA, as there is a weaker correlation between diameter and risk of rupture in
- 77 this type of AAA.
- The decrease in classical monocytes could be a useful surrogate marker for AAA
- volume and provide additional information on AAA diameter.
- Monocyte shifts and their association with AAA disease may be relevant for the
- diagnosis of AAA and should be verified in larger cohorts.
- The mechanisms behind the decrease in classical monocytes and the increase in
- intermediate and non-classical subsets should be investigated in further *in vitro* studies
- as they offer therapeutic potential.

### Introduction

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Abdominal aortic aneurysm (AAA) is a life-threatening condition with high mortality rates. Main pathological features are inflammation with increased local cytokine production, extracellular matrix degradation, oxidative stress and the loss of smooth muscle cells. The only effective treatment is surgical elimination of the AAA. Pharmacological treatments are still lacking, emphasizing the need to define the pathomechanisms that contribute to the initiation and progression of the disease. Inflammatory cells in AAA comprise monocytes, macrophages, neutrophils, mast cells, natural killer (NK) cells, T and B cells and dendritic cells.<sup>2</sup> Monocytes are recruited at sites of inflammation where they differentiate into macrophages.<sup>3</sup> Monocytes exist in subsets, which differ in morphology, function and cell surface marker (e.g. chemokine receptors) expression. Three distinct subsets were distinguished in humans based on the expression of the the LPS-receptor CD14 and the Fcy receptor CD16: classical (CD14++CD16-), non-classical (CD14+CD16++) and intermediate (CD14++CD16+) monocytes.<sup>4</sup> Classical monocytes (CD14++CD16-) secrete large amounts of pro-inflammatory cytokines and promote angiogenesis, wound healing and coagulation, demonstrating their importance in tissue repair.<sup>3</sup> In contrast, CD16-expressing cells may secrete pro-inflammatory cytokines, have a high antigen-presenting capacity and the ability to migrate into subendothelial spaces and atherosclerotic lesions.<sup>4</sup> These cells include intermediate monocytes (CD14++CD16+), that secrete pro-inflammatory cytokines and accumulate in chronic inflammatory diseases.<sup>3,5,6</sup> Intermediate subsets are predictive for cardiovascular disease<sup>4</sup> and are associated, for example, with susceptibility to plaque vulnerability<sup>3</sup>. CD16+ subsets are elevated in patients with AAA<sup>7</sup> and a recently published study showed that only intermediate monocytes (CD14++CD16+) were elevated in AAA compared to healthy individuals and patients with PAD<sup>8</sup>. Interestingly, CD14++CD16+ and D-

110

111

112

113

114

115

116

117

118

119

120

121

122

123

dimer proved to be suitable diagnostic markers for AAA while elevated concentrations of these subsets were able to predict rapid growing AAA.8 Non-classical monocytes have low expression of CD14 (CD14+) and secrete pro- and antiinflammatory cytokines. These monocytes have phagocytic properties to remove cell debris and are important for patrolling the vascular endothelium and controlling vascular integrity. Most likely, they are involved in the resolution of inflammation.<sup>3</sup> However, it should be noted that a CD14-low subset may promote neovascularization and destabilization of lesions, while their accumulation in ischemic tissue may have beneficial effects.<sup>4</sup> Although an increase in intermediate subsets has been demonstrated in AAA, it is still under debate whether the three subgroups correlate with AAA diameter, AAA volume, and thickness of the intraluminal thrombus as the main morphologic features of AAA and could be useful surrogate markers. In addition, there is no information whether any of these monocyte subsets can predict end-stage AAA, when most patients with AAA are diagnosed. Here, we aimed to comprehensively define associations of circulating monocyte phenotypes with AAA risk and AAA morphology.

### **Materials and Methods**

**Study Design** 

Monocyte subpopulations were determined in an observational study in electively treated AAA patients and patients with varicose veins who served as controls. Due to the observational nature of the study, no sample size or power calculation was performed, according to the STROBE guidelines. Patients were treated in the Department of Visceral, Thoracic and Vascular Surgery between December 2020 and June 2024. The diagnostic criteria for varicose patients included venous reflux assessed by duplex ultrasound and signs of chronic venous insufficiency according to the CEAP classification. Inclusion criteria were age over 50 years and no known history of arterial disease, T2D and infectious diseases. Patients with thrombophlebitis were excluded. Inclusion criteria for AAA patients were a diameter of the infrarenal aorta of more than 40 mm, a rapidly growing AAA with more than 10 mm progression per year or a symptomatic AAA. The study was approved by the ethics committee of the Technische Universität Dresden (EK 151042017). Informed consent was obtained from all study participants.

### **Outcome Variables**

Counts of each monocyte subset were defined as the primary outcome variable in the multivariate logistic regression, while AAA disease was defined as the outcome variable in the hazard ratio analysis.

#### **Clinical Parameters**

Serum low-density (LDL) and high-density (HDL) lipoprotein, total cholesterol (TC), triglycerides, non-fasting glucose, hemoglobin (Hb), leukocyte, and C-reactive protein (CRP) concentrations were analyzed in the Institute for Clinical Chemistry and Laboratory Medicine at the TU Dresden using standard laboratory methods. Due to the lack of data on blood

chemistry or medical therapies, the number of analyzed patients varies in each group. Cardiovascular risk factors, comorbidities, and prescribed medical therapies were evaluated retrospectively. Hypertension, type 2 diabetes (T2D), heart failure (HF), peripheral artery disease (PAD), and carotid artery stenosis (CAS) were defined by a past documented history of diagnosis or any treatment for these diseases. CAD was defined by a history of myocardial infarction, angina, or treatment for CAD. Smoking was defined as any history of smoking and sex was self-reported.

### **Analysis of AAA Diameter and AAA Morphology**

The aortic diameter, maximal intraluminal thrombus depth and aortic volumes were determined as described previously. In brief, aortic diameter was assessed by computed tomography angiography by measuring the distance between the outer adventitia (outer-to-outer-edge) by a single trained observer. Thickness of the ILT was determined in the arterial phase on CT scans following multiplanar reconstruction. The aorta was scanned in an axial position in 1 mm sections. The thickness of the ILT was assessed at the largest distance from the inner surface of the lumen to the outer aortic wall. The AAA volume was measured by two trained people using the automatic segmentation model of the IMPAX EE R20 software (Agfa HealthCare, Mortsel, Belgium). The aorta was scanned with contrast media in the arterial phase in 1 mm sections. The outer wall of the aneurysm and the true lumen were selected manually every 6 mm in the transverse plane. The starting point of the measurement was defined as the cranial end of the aneurysm with a diameter greater than 30 mm. The measurement ended caudal to the dilation or at the aortic bifurcation. Non-recognized areas were cropped manually. The volume of AAA is given in cm<sup>3</sup>. The ILT was included in the total AAA volume measurement but was not specifically tagged for segmentation.

**Blood Samples and Flow Cytometry** 

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

Non-fasting venous blood was collected pre-operatively between 2020 and 2024 in 9 mL S-Monovette EDTA (Sarstedt, Nürmbrecht, Germany). Monocyte subpopulations were analyzed using flow cytometry. Cells were stained for 10 min using the following antibody cocktail: CD45-FITC (HI-30, Thermo Fisher Scientific, Darmstadt, Germany), CD16-PerCP710 (CB16, Thermo Fisher Scientific Darmstadt, Germany) and CD14-PE (MφP9, BD Biosciences, Heidelberg, Germnay). Isotype controls were prepared to ensure selectivity of the antibodies. Afterwards, erythrocytes were lysed by the addition of FACS lysing solution (BD Biosciences, Heidelberg, Germnay) for 10 min. Data acquisition was performed on LSR Fortessa (BD Biosciences, Heidelberg, Germnay) and LSR II (BD Biosciences, Heidelberg, Germnay). Data analysis was performed using FlowJo<sup>TM</sup> Software (Version 10, BD Biosciences, Heidelberg, Germnay). First, debris was excluded by applying SSC and FSC, and events with low FSC and SSC signals were omitted. Before cell aggregates were excluded from the analysis, expression of CD45 against the SSC signal was used to select the monocyte population for further analysis. Finally, classical (CD14++CD16-), non-classical (CD14+CD16++) and intermediate (CD14++CD16+) monocytes were determined according to their expression of CD14 and CD16 (Supplementary Figure 1).

### **Statistics**

Graph Pad Prism 10.0 (GraphPad Software, Inc., La Jolla, CA, USA) and R Core Team (2021) R: A Language and Environment for Statistical Computing software (R Foundation for Statistical Computing, Vienna/Austria) were used for statistical analysis. A *P*-value ≤0.05 was considered significant. Outliers were tested with the Grubbs outlier test and normality distribution with the D'Agostino and Pearson test. According to the result of the normal distribution test, Mann–Whitney U or unpaired t-test were used to compare AAA and varicose

200

201

202

203

204

205

206

207

208

209

210

vein patients. Data are shown as box plots with individual values or as scatter dot plots, as indicated in the figure legends. Correlational analysis was done using Pearson correlation (r<sub>P</sub>). Weighted linear regression was performed for variable selection, to assess the influence of age, sex, smoking, hypertension, T2D, CAD, PAD, CRP, HDL-, LDL cholesterol, triglyceride, hemoglobin, leukocyte count, AAA diameter, thickness of the ILT and prescription of insulin, diuretics, statins, ACE, CCB, ARBs, β-blocker, ASA and therapeutic anticoagulation. As some comorbidities strongly influence each other, only age and sex were included in the final analysis. In addition, PAD was included in the multivariate analysis as patients already served as a control group in numerous studies. <sup>8</sup> Data were analyzed by multivariate logistic regression using each of the monocyte subgroups as a indepedent variable for the presence of AAA disease. Subgroup concentrations were log transformed, and the effect of risk factors was compared with patients in whom the risk factor was not present.

Results

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

### **Patient Characteristics**

The comparison of AAA and venous vein patient's revealed that the AAA group was significantly older and comprised more male patients than varicose vein controls. As expected, both groups differed in their prevalence of cardiovascular risk factors and prescribed pharmacotherapy. A detailed list of risk factors and pharmacotherapy is given in **Table 1**.

## Phenotypic Heterogeneity of Monocyte Subsets in AAA Patients

In the present study, significants shifts in monocyte subsets were observed in AAA patients compared to controls with varicose veins. In patients with an AAA, there were 1.6-fold lower (P=0.001) counts for classical monocytes and 1.9-fold (P=0.025) and 1.8-fold (P=0.019)higher counts for non-classical monocytes and intermediates, respectively (Figure 1). To determine which of the patients' risk factors and comorbidities influenced the subgroups the most, we performed a linear weighted regression. We found that classical monocytes are relatively robust, since they are barely affected by any of the investigated comorbidities and risk factors (Supplementary Table 1). In non-classical monocytes, PAD was associated with an increase, and T2D as well as hypertension were associated with a decrease in this subset (Supplementary Table 2). Intermediate monocytes were strongly influenced by the presence of T2D, while sex and hypertension were associated with a decrease in this subset (Supplementary Table 3). All the investigated comorbidities and risk factors were seen to highly confound each other. We therefore performed a logistic regression analysis and chose age, sex and PAD for adjustment to analyze whether these factors influence the observed differences between varicose veins and AAA. After adjusting for age, sex and PAD the observed decrease in classical monocytes (P=0.001) and increase in non-classical monocytes (P=0.040) in AAA patients remained significant (**Table 2**).

Monocyte Subsets, AAA Risk and Associations with AAA Morphology

Hazard ratios were calculated to test whether differences in monocyte subgroups lead to an increased risk of AAA disease. A reduced number of classical monocytes was associated with an increased risk of AAA (*P*=0.002). Furthermore, increased levels of non-classical (*P*=0.030) and intermediate monocytes (*P*=0.006) led to a higher risk for AAA disease (**Table 3**).

Monocytes and Correlations with AAA Morphology

A correlational analysis was performed to test whether the different monocyte subgroups correlate with the morphology of the AAA and can therefore serve as surrogate markers. Classical monocytes showed a trend to increase with AAA diameter (**Figure 2A**), while no correlations with AAA volume or ILT thickness were found (**Table 4**). Conversely, non-classical monocytes decreased with increasing AAA diameter (rp=-0.64, *P*<0.001) and increasing AAA volume (rp=-0.50, *P*=0.003) (**Figure 2B,C**). Intermediate monocytes showed a trend towards a positive association with maximum depth of the ILT (rp=0.32, *P*=0.067)

(Figure 2D). Table 4 provides an extended overview of the tested correlations.

### Discussion

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

Monocytes are important inflammatory mediators in cardiovascular disease and also in AAA as a particular CVD. Depending on the expression of their surface markers, monocytes are classified into different subgroups that have different functions. Knowledge about their expression patterns may contribute to the understanding of specific disease mechanisms as these cells migrate into inflamed tissue and differentiate into macrophages. Moreover, this would allow the identification of patients at high risk and provide useful surrogate markers for AAA morphology. Although an increase in intermediate subsets has been demonstrated in AAA<sup>8</sup>, nothing is known whether these subsets correlate with AAA diameter, AAA volume and intraluminal thrombus as main morphologic features of AAA. Determination of surrogate markers that correlate with the maximum AAA diameter is of great interest, as the AAA diameter is the most important marker for decisions on surgical therapy. 12 Furthermore, there is no information on whether any of these subgroups can predict the risk of having AAA. The present study showed a lower count of classical monocytes (CD14++CD16-) and higher counts of intermediate (CD14++CD16+) and non-classical monocytes (CD14+CD16++) in patients with AAA. Our data are, at least in part, supported by previously published studies.<sup>7,8</sup> The decreased proportion of classical monocytes could be explained by findings in mice after induction of acute myocardial infarction. In the first phase, CD14+CD16- monocytes accumulate early at the site of injury to clear necrotic debris and promote healing of the damaged tissue. CD14+CD16++ dominate in the second phase and promote healing through the accumulation of myofibroblasts, angiogenesis and collagen deposition.<sup>13</sup> The data herein eventually underline an imbalance between both subsets in patients with AAA towards intermediate subsets that promote fibrotic remodeling in the AAA wall. While non-classical monocytes remain in the bloodstream, classical monocytes could transmigrate through the

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

endothelium into the vessel wall. 14 This could be a possible explanation for the depletion of the classic monocytes, which could be due to an increased migration into the AAA. Non-classical monocytes are the most inflammatory subset but also show patrolling function.<sup>15</sup> Studies in patients with CAD16 and subclinical atherosclerosis demonstrated increased nonclassical subsets<sup>17</sup> and therefore coincidence the data of the present study. Herein, a higher count of non-classical was found in AAA, which is different to data previously published by Klopf et al. Most often, patients with PAD served as controls in biomarker studies in AAA. 18 PAD is one of the most common initial manifestations of T2D<sup>19</sup> and T2D itself is inversely associated with AAA disease. 20 It might be of speculation that a confounding of protective and adverse effects could occur. To further understand the link between AAA risk and blood monocytes, we analyzed whether a specific subtype of monocyte was associated with increased risk of having AAA disease. We were able to show that a lower proportion of classical monocytes was associated with a higher risk of AAA, while an increase in non-classical and intermediate monocytes was associated with an increased risk of AAA. It could be that the increase in intermediate and non-classical subsets occurs at the expense of classical monocytes. Similar results were demonstrated in patients with T2D.<sup>21</sup> Intermediate monocytes have been demonstrated to be an independent predictor of cardiovascular events in patients with atherosclerotic diseases.<sup>22</sup> Similar results were obtained for non-classical monocytes.<sup>22</sup> The increased risk might be explained by the proinflammatory role of intermediate and non-classical monocytes.<sup>22</sup> Interestingly, the percentage of classical monocytes might be a protective factor for major adverse outcomes in coronary artery disease.<sup>23</sup> Classical monocytes are known to be phagocytic but have no inflammatory potential. 15 Given their protective role, the decrease in AAA and their association with AAA risk might be a hint to a loss of their function.

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

The higher percentage of non-classical, CD14+CD16++ monocytes was inversely associated with the AAA diameter and AAA volume. Analyzing the AAA volume has the advantage of including the morphology of the aneurysm.<sup>24</sup> AAA volume can be useful when the diameter fails or for monitoring saccular AAA, since there is a weaker correlation between increased diameter and rupture risk in this type of AAA.<sup>25</sup> Finally, AAA volume might be a better predictor for AAA growth.<sup>26</sup> A negative correlation between non-classical, CD14+CD16++ monocytes with the intima-media-thickness was shown in patients with carotid artery stenosis<sup>27</sup> and in peripheral artery disease where non-classical subsets decreased with the severity<sup>5</sup>. CD14+CD16++ monocytes (or Ly-6Clo in mice) are involved in healing of the ischemic myocardium and they initiate the differentiation towards M2 macrophages, known to be involved in tissue repair. It might be of speculation, but the inverse relationship could be explained by temporal patterns and lack of their protective and healing functions<sup>27</sup>, although they are higher in patients with AAA. Another possibility that could explain the inverse relationship between AAA diameter and non-classical monocytes is that non-classical monocytes migrate into the AAA, i.e. as the diameter increases, more cells migrate in and their concentration in the blood decreases. In addition, the patients examined here are in the final stage of the disease and exhibit the typical degeneration of the AAA wall. 18,28 The majority of AAA are covered by an intraluminal thrombus (ILT). The ILT contains fibrin, inflammatory cells, platelets and red blood cells and affects growth and rupture of the AAA.<sup>29,30</sup> Herein, intermediate (CD14++CD16+) subsets tended to correlate with the thickness of the ILT in AAA-patients. Intermediate monocytes are capable of antigen presentation, secreting pro-inflammatory cytokines and to regulate immune responses.<sup>31</sup> It has been demonstrated that intermediate monocytes are present in the ILT but in lower amounts than in peripheral blood of AAA patients.<sup>32</sup> The positive association could reflect the inflammatory nature of the ILT or also cells that are released by the ILT.

325

326

327

328

329

330

331

Overall, the present study showed age- and sex-independent shifts in classical, non-classical and intermediate subsets in AAA, suggesting disease-specific mechanisms. An decrease in classical monocytes and the increases in intermediate and non-classical monocytes were associated with risk for having AAA. The number of non-classical monocytes correlated inversely with AAA diameter and AAA volume and could therefore be a useful surrogate marker for AAA morphology, beyond the AAA diameter. Especially the lowering in phagocytic classical monocytes and the increase in non-classical monocytes should be considered in future studies.

Limitations

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

The present study is a descriptive, observational study on a very small cohort of patients. Varicose vein patients were used as a control group and their limitation is their different comorbidity and risk factor profile. The relativley small number of patients included and the large number of confounding factors may have influenced the results. Analyzing patients in whom the risk factors have been adjusted prior, e.g. in a case-control study, could minimize these effects. Furthermore, the results obtained here do not allow to establish a causal relationship between the different monocyte subsets and the development of AAA which is due to the study design. Finally, the main discrepancy when comparing data from flow cytometry with the present study is the pre-selection of cells, the declaration of subgroups based on the expression of CD14 and CD16 and the gating strategy in flow cytometry.

### Acknowledgement

Flow cytometry measurement and analysis was done at the Flow Cytometry Core Facility at

TU Dresden, University of Technology. We would like to thank Dr Anne Gompf, Head of the

Flow Cytometry Core Facility, for her excellent technical experience.

### **Figures**

348

349

350

351

352

353

354

355




Figure 1: Monocyte Subsets in Patients with AAA and Varicose Vein Controls. Nonfasting venous-blood was collected and the relative frequency of the individual monocyte subpopulations was determined by flow cytometry. A, classical (CD14++CD16-), B, nonclassical (CD14+CD16++) and C, intermediate (CD14++CD16+) monocytes. All data are shown as boxplots with individual values. Outliers were identified using the Grubb's outlier test and one patient in each group was excluded from all further analysis. A, Unpaired t-test, **B-C**, Mann-Whitney U test.




Figure 2: Correlation of Monocyte Subsets and AAA Morphology. Monocyte subsets were analyzed using flow cytometry and are given as % of total monocytes. The data were logarithmically transformed and analyzed for correlations with the morphology of the AAA. Correlation of A, classical monocytes with AAA diameter, B, AAA diameter and non-classical monocytes, C, non-classical monocytes and AAA volume and D, ILT and intermediate monocytes. Statistics: Grubb's outlier test was used to identify outliers. One AAA patient was identified as an outlier and excluded from all further analysis. Correlational analysis was done using the Pearson correlation. r<sub>P</sub>, Pearson rank correlation coefficient.

358

359

360

361

362

363

364

**Tables** 

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

Table 1: Clinical Characteristics in Patients with Abdominal Aortic Aneurysm (AAA) and Venous Vein varicose. Blood was taken in the non-fasted state. Reference values for the corresponding blood parameters are given in the table. Reference values for LDL and total cholesterol (TC) are based on the European Society of Cardiology (ESC) recommendations. Reference values for fasting glucose were excluded due to the withdrawal in the non-fasted state. Statistics: All data are presented as median with minimum and maximum values. Comparison of continuous data was done using the Mann-Whitney U test or t-test. Discrete data were analyzed by Chi-Square test. For t test (a) t-statistic is reported, Mann-Whitney (b) U statistics and Chi-square (c)  $X^2$  is reported. Abbreviations: ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blocker; BMI, body mass index; ASA, acetylsalicylic acid; CAD, coronary artery disease; CCB, calcium channel blocker; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery disease; T2D, type 2 diabetes mellitus; TIA, transient ischemic attack.

Observational study							
	Varicosis eAAA P-value Statis						
Baseline demographics							
n included	33	33					
Age – years, mean ± SD	62.79 ± 8.15	$70.39 \pm 9.41$	<0.001 <sup>a</sup>	t=3.51			
Sex, male:female, % male	20:13, 61	30:3, 91	0.0041°	X <sup>2</sup> =8.25			

Hematology							
Hemoglobin – mmol/L, mean	Hemoglobin – mmol/L, mean $8.99 \pm 0.73$ $9.01 \pm 1.10$ $0.948^a$						
± SD, n	32	32 33					
Reference values 8.60 – 12.10 mmol/L							
Leukocytes – GPt/L, mean ±	$6.83 \pm 1.48$	$7.64 \pm 1.68$	0.046 <sup>a</sup>	t=2.04			
SD, n	32	33					
Reference values 3.8 – 9.8 GPt/I							
Cardiovascular risk factors							
LDL cholesterol – mmol/L,	$4.18 \pm 1.50$	$3.28 \pm 1.36$	0.014 <sup>a</sup>	t=2.53			
mean $\pm$ SD, n	31	33					
Reference values	<1.40 mmol/L for	people with very	-high risk				
HDL cholesterol – mmol/L,	1.63	1.28	0.015 <sup>b</sup>	U=331.00			
median with range, n	(1.00 - 2.62)	(0.75 - 1.98)					
	31	33					
Reference values >0.90 mmol/L for men and >1.10 mmol/L for women							
Total cholesterol – mmol/L, $4.57 \pm 1.37$ $3.52 \pm 1.55$ $0.006^a$							
mean $\pm$ SD, n 31							
Reference values <4.00 mmol/L							

m: 1 17	1.10	1.20	0.50 <b>2</b> h	11 455 50			
Triglycerides – mmol/L,	1.18	1.20	0.582 <sup>b</sup>	U=455.50			
median with range, n	(0.43 - 3.88)	(0.52 - 3.59)					
	31	32					
Refe	Reference values 0.35 – 1.70 mmol/L						
Blood glucose – mmol/L,	5.37	5.94	0.004 <sup>b</sup>	U=238.50			
median with range, n	(4.30 – 6.81)	(4.69 – 11.33)					
	28	30					
Reference	value only for fas	ting glucose possi	ble				
CRP – mg/L, median with	1.30	2.65	0.049 <sup>b</sup>	U=353.50			
range, n	(0.50 - 21.30)	(0.60 - 16.80)					
	31	31					
	Reference values	<5.0 mg/L	l				
Smoking, yes:no – %	6:27, 18	23:10, 70	<0.001°	X <sup>2</sup> =17.78			
Hypertension, yes:no – %	11:22, 33	30:3, 91	<0.001°	X <sup>2</sup> =23.24			
CAD, yes:no – %	0:33, 0	10:23, 30	0.001°	X <sup>2</sup> =11.79			
HF, yes:no – %	1:32, 3	10:23, 30	0.003°	X <sup>2</sup> =8.84			
CAS, yes:no – %	0:33, 0	7:26, 21	0.005°	X <sup>2</sup> =7.83			
PAD, yes:no – %	0:33, 0	8:25, 24	0.003°	X <sup>2</sup> =9.10			
T2D, yes:no – %	0:33, 0	11:22, 33 <0.001°		X <sup>2</sup> =13.20			
	L	I	1	I			

BMI – kg/m², median with	27.20	27.25	0.677 <sup>b</sup>	U=511.50	
range, n	(21.20 – 40.70)	(20.30 – 38.01)			
	33	33			
Pharmacological therapies					
Statins, yes:no – %	3:29, 9	24:9, 73	<0.001°	X <sup>2</sup> =26.85	
ACE inhibitors, yes:no – %	3:29, 9	15:18, 45	0.001°	X <sup>2</sup> =10.56	
ARB, yes:no – %	4:28, 13	13:20, 39	0.014 <sup>c</sup>	X <sup>2</sup> =6.08	
CCB, yes:no – %	2:30, 6	13:20, 39	0.002°	X <sup>2</sup> =10.05	
ASA, yes:no – %	2:30, 6	25:8, 76	<0.001°	X <sup>2</sup> =32.32	
b-blocker, yes:no – %	4:28, 13	17:16, 52	<0.001°	X <sup>2</sup> =11.31	
Anticoagulation, yes:no – %	6:26, 19	3:30, 9	0.260 <sup>c</sup>	X <sup>2</sup> =1.27	
Antiplatelet, yes:no – %	1:31, 3	3:30, 9	0.317 <sup>c</sup>	X <sup>2</sup> =1.00	
Diuretics, yes:no – %	4:28, 13	9:24, 27	0.137°	X <sup>2</sup> =1.49	
T2D treatment, yes:no – %	0:32, 0	11:22, 33	<0.001°	X <sup>2</sup> =12.84	
Insulin, yes:no – %	0:32, 0	2:31, 6	0.157°	X <sup>2</sup> =2.00	

383

384

385

386

387

388

389

390

391

392

393

394

395

396

Table 2: Differences in Monocyte Subsets after Adjusting to Age, Sex and PAD. Monocyte subsets were analyzed using flow cytometry and monocytes are given in % of total monocytes. Data were analyzed by multivariate logistic regression using each of the monocyte subgroups as a diagnostic variable for the presence of AAA disease. The monocyte subgroups were logarithmically transformed, and data were analyzed by multivariate logistic regression using the corresponding subset as a predictor variable. The effects of each risk factor were compared with patients in whom the risk factor was not present (ref=none). The odds ratio (OR) refers to the relative increase in risk of AAA disease as the percentage of the subgroup increases on the logarithmic scale. For sex, ORs refer to men and reference values refer to women. AAA diameter and age show the increase per unit (year and mm, respectively). Unadjusted values were obtained by pairwise comparison of each variable listed in the table with the outcome of having an AAA. Adjusted values were analyzed by holding the effects of the other variables constant and assuming an increase in the monocyte subset on the logarithmic scale. Abbreviations: OR, odds ratio.

Variable	Unadjusted OR [95% CI]	P-value	Adjusted OR [95% CI]	P-value
	classical mor	nocytes [log]	10]	
Group (ref=varicosis)	0.973 [0.958, 0.987]	<0.001	0.968 [0.949, 0.987]	0.001
Age (years)	0.999 [0.998, 1.000]	0.076	1.000 [0.999, 1.001]	0.950
Sex (ref=female)	1.001 [0.982, 1.021]	0.895	1.014 [0.994, 1.035]	0.160

PAD (ref=none)	0.987 [0.963, 1.012]	0.308	1.004 [0.980, 1.029]	0.754
	non-classical ı	monocytes [le	og10]	
Group	1.504 [1.019, 2.220]	0.040	1.760 [1.058, 2.928]	0.030
(ref=varicosis)				
Age (years)	1.002 [0.981, 1.024]	0.830	0.988 [0.964, 1.012]	0.331
Sex (ref=female)	1.024 [0.635, 1.652]	0.921	0.784 [0.462, 1.330]	0.360
PAD (ref=none)	1.283 [0.697, 2.360]	0.417	1.026 [0.537, 1.960]	0.937
	intermediate I	Monocytes [l	og10]	
Group	1.674 [0.988, 2.836]	0.055	1.940 [0.987, 3.814]	0.054
(ref=varicosis)				
Age (years)	1.024 [0.996, 1.053]	0.091	1.007 [0.975, 1.040]	0.680
Sex (ref=female)	0.709 [0.375, 1.343]	0.287	0.563 [0.279, 1.136]	0.107
PAD (ref=none)	1.203 [0.527, 2.745]	0.656	0.857 [0.363, 2.024]	0.721

Table 3: Hazard Ratios of Monocyte Subsets and AAA risk. Monocyte subsets were analyzed using flow cytometry and monocytes are given in % of total monocytes. Logistic regression was used to obtain hazard ratio of incident AAA per one unit increase in monocytes subsets on log scale.

400

401

402

	Hazard Ratio [95% CI]	<i>P</i> -value
Classical monocytes	0.726 [0.584, 0.874]	0.002
Intermediate monocytes	1.412 [1.123, 1.846]	0.006
Non-classical monocytes	1.537 [1.068, 2.354]	0.030

Monocyte subsets were analyzed using flow cytometry and monocyte subsets are given in % of total monocytes. Data were log transformed. Correlational analysis was performed using

Table 4: Summary of Correlations Between Monocyte Subsets and AAA Morphology.

Pearson correlation. Outliers were identified using Grubb's outlier test and excluded from

further analysis. Abbreviations: AAA, Abdominal aortic aneurysm, ILT, Intraluminal

thrombus, rp, Pearson's rank correlation coefficient.

404

405

406

407

408

409

410

	classical monocytes		non-classical		intermediate	
			monocytes		monocytes	
	rp	P-value	rp	P-value	rp	P-value
AAA	0.32	0.069	-0.64	<0.001	-0.20	0.265
diameter						
ILT	-0.21	0.23	0.19	0.298	0.32	0.067
AAA	0.27	0.13	-0.50	0.003	-0.13	0.481
volume						

412 References

- 413 Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Monocytes and 414 macrophages in abdominal aortic aneurysm. Nat Rev Cardiol. 2017;14:457–471. doi: 415 10.1038/nrcardio.2017.52
- 416 2. Márquez-Sánchez AC, Koltsova EK. Immune and inflammatory mechanisms of 417 abdominal aortic aneurysm. Front Immunol. 2022;13:989933. 418 10.3389/fimmu.2022.989933
- 419 Ruder AV, Wetzels SMW, Temmerman L, Biessen EAL, Goossens P. Monocyte 420 heterogeneity in cardiovascular disease. Cardiovasc Res. 2023;119:2033-2045. doi: 421 10.1093/cvr/cvad069
- Hristov M, Leyendecker T, Schuhmann C, Hundelshausen P von, Heussen N, Kehmeier 422 423 E, Krötz F, Sohn H-Y, Klauss V, Weber C. Circulating monocyte subsets and 424 cardiovascular risk factors in coronary artery disease. Thromb Haemost. 2010;104:412-425 414. doi: 10.1160/TH10-01-0069
- 426 Wildgruber M, Aschenbrenner T, Wendorff H, Czubba M, Glinzer A, Haller B, Schiemann M, Zimmermann A, Berger H, Eckstein H-H, Meier R, Wohlgemuth WA, 427 428 Libby P, Zernecke A. The "Intermediate" CD14++CD16+ monocyte subset increases in 429 severe peripheral artery disease in humans. Sci Rep. 2016;6:39483. 430 10.1038/srep39483
- 431 van der Laan AM, Hirsch A, Robbers LFHJ, Nijveldt R, Lommerse I, Delewi R, van der 432 Vleuten PA, Biemond BJ, Zwaginga JJ, van der Giessen WJ, Zijlstra F, van Rossum AC, 433 Voermans C, van der Schoot CE, Piek JJ. A proinflammatory monocyte response is 434 associated with myocardial injury and impaired functional outcome in patients with ST-435 segment elevation myocardial infarction: monocytes and myocardial infarction. Am Heart 436 J. 2012;163:57-65.e2. doi: 10.1016/j.ahj.2011.09.002
- 437 Ghigliotti G, Barisione C, Garibaldi S, Brunelli C, Palmieri D, Spinella G, Pane B, 7. 438 Spallarossa P, Altieri P, Fabbi P, Sambuceti G, Palombo D. CD16(+) monocyte subsets 439 are increased in large abdominal aortic aneurysms and are differentially related with 440 circulating and cell-associated biochemical and inflammatory biomarkers. Dis Markers. 441 2013;34:131-142. doi: 10.1155/2013/836849
- 442 Klopf J, Zagrapan B, Brandau A, Lechenauer P, Candussi CJ, Rossi P, Celem ND, Ziegler 8. 443 M, Fuchs L, Hayden H, Krenn CG, Eilenberg W, Neumayer C, Brostjan C. Circulating 444 monocyte populations as biomarker for abdominal aortic aneurysms: a single-center 445 retrospective cohort study. Front Immunol. 2024;15:1418625. doi: 446 10.3389/fimmu.2024.1418625
- 447 Vandenbroucke JP, Elm E von, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole 448 C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in 449 Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. doi: 450 10.1371/journal.pmed.0040297
- 451 10. Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H, Bush RL, Blebea J, 452 Carpentier PH, Maeseneer M de, Gasparis A, Labropoulos N, Marston WA, Rafetto J, 453 Santiago F, Shortell C, Uhl JF, Urbanek T, van Rij A, Eklof B, Gloviczki P, Kistner R, 454 Lawrence P, Moneta G, Padberg F, Perrin M, Wakefield T. The 2020 update of the CEAP 455 classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 456 2020;8:342–352. doi: 10.1016/j.jvsv.2019.12.075
- 457 11. Hamann B, Klimova A, Klotz F, Frank F, Jänichen C, Kapalla M, Sabarstinski P, Wolk S, 458 Morawietz H, Poitz DM, Hofmann A, Reeps C. Regulation of CD163 Receptor in Patients 459 with Abdominal Aortic Aneurysm and Associations with Antioxidant Enzymes HO-1 and

460 NQO1. Antioxidants (Basel). 2023;12. doi: 10.3390/antiox12040947

- 461 12. Wanhainen A, Mani K, Golledge J. Surrogate Markers of Abdominal Aortic Aneurysm 462 Progression. Arterioscler Thromb Vasc Biol. 2016;36:236-244. doi: 463 10.1161/ATVBAHA.115.306538
- 464 13. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo J-L, 465 Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 466 467 2007:204:3037-3047. doi: 10.1084/jem.20070885
- 14. Feinstein MJ, Doyle MF, Stein JH, Sitlani CM, Fohner AE, Huber SA, Landay AL, 468 469 Heckbert SR, Rice K, Kronmal RA, Hedrick C, Manichaikul A, McNamara C, Rich S, 470 Tracy RP, Olson NC, Psaty BM, Delaney JAC. Nonclassical Monocytes 471 (CD14dimCD16+) Are Associated With Carotid Intima-Media Thickness Progression for 472 Men but Not Women: The Multi-Ethnic Study of Atherosclerosis-Brief Report. 473 Arterioscler Thromb Vasc Biol. 2021;41:1810-1817. doi: 474 10.1161/ATVBAHA.120.315886
- 475 15. Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B. 476 Non-Classical monocytes display inflammatory features: Validation in Sepsis and 477 Systemic Lupus Erythematous. Sci Rep. 2015;5:13886. doi: 10.1038/srep13886
- 478 16. Urbanski K, Ludew D, Filip G, Filip M, Sagan A, Szczepaniak P, Grudzien G, Sadowski 479 J, Jasiewicz-Honkisz B, Sliwa T, Kapelak B, McGinnigle E, Mikolajczyk T, Guzik TJ. 480 CD14+CD16++ "nonclassical" monocytes are associated with endothelial dysfunction in 481 patients with coronary artery disease. Thromb Haemost. 2017;117:971-980. doi: 482 10.1160/TH16-08-0614
- 483 17. Poitou C, Dalmas E, Renovato M, Benhamo V, Hajduch F, Abdennour M, Kahn J-F, 484 Veyrie N, Rizkalla S, Fridman W-H, Sautès-Fridman C, Clément K, Cremer I. 485 CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: 486 relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 487 2011;31:2322–2330. doi: 10.1161/ATVBAHA.111.230979
- 488 18. Hofmann A, Khorzom Y, Klimova A, Wolk S, Busch A, Sabarstinski P, Müglich M, 489 Egorov D, Kopaliani I, Poitz DM, Kapalla M, Hamann B, Frank F, Jänichen C, Brunssen 490 C, Morawietz H, Reeps C. Associations of Tissue and Soluble LOX-1 with Human 491 Abdominal Aortic Aneurysm. JAm Heart Assoc. 2023;12:e027537. 492 10.1161/JAHA.122.027537
- 493 19. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, 494 Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of 495 cardiovascular diseases: a cohort study in 1.9 million people. *Lancet Diabetes Endocrinol*. 496 2015;3:105–113. doi: 10.1016/S2213-8587(14)70219-0
- 497 20. Tsai C-L, Lin C-L, Wu Y-Y, Shieh D-C, Sung F-C, Kao C-H. Advanced complicated 498 diabetes mellitus is associated with a reduced risk of thoracic and abdominal aortic 499 aneurysm rupture: a population-based cohort study. Diabetes Metab Res Rev. 500 2015;31:190-197. doi: 10.1002/dmrr.2585
- 501 21. Julia J-B, Girard D, Diedisheim M, Saulnier P-J, Tran Vuong B, Blériot C, Carcarino E, 502 Keizer J de, Orliaguet L, Nemazanyy I, Potier C, Khider K, Tonui DC, Ejlalmanesh T, 503 Ballaire R, Mambu Mambueni H, Germain S, Gaborit B, Vidal-Trécan T, Riveline J-P, 504 Garchon H-J, Fenaille F, Lemoine S, Carlier A, Castelli F, Potier L, Masson D, Roussel 505 R, Vandiedonck C, Hadjadj S, Alzaid F, Gautier J-F, Venteclef N. Blood Monocyte 506 Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes. Circ Res. 507 2024;134:189–202. doi: 10.1161/CIRCRESAHA.123.322757
- 508 22. Hristov M, Weber C. Monocyte Subsets in Cardiovascular Disease: A Biomarker 509 Perspective. Thromb Haemost. 2024. doi: 10.1055/a-2348-5697

- 510 23. Dregoesc MI, Tigu AB, Bekkering S, van der Heijden CDCC, Rodwell L, Bolboacă SD, 511 Joosten LAB, Netea MG, Riksen NP, Iancu AC. Intermediate monocytes are associated 512 with the first major adverse cardiovascular event in patients with stable coronary artery
- 513 disease. Int J Cardiol. 2024;400:131780. doi: 10.1016/j.ijcard.2024.131780
- 514 24. Kitagawa A, Mastracci TM, Allmen R von, Powell JT. The role of diameter versus volume 515 as the best prognostic measurement of abdominal aortic aneurysms. J Vasc Surg. 516 2013;58:258–265. doi: 10.1016/j.jvs.2013.05.001
- 25. Vaitėnas G, Mosenko V, Račytė A, Medelis K, Skrebūnas A, Baltrūnas T. Abdominal 517 518 Aortic Aneurysm Diameter versus Volume: A Systematic Review. Biomedicines. 519 2023:11. doi: 10.3390/biomedicines11030941
- 520 26. Lindquist Lilieqvist M, Hultgren R, Gasser TC, Roy J. Volume growth of abdominal aortic 521 aneurysms correlates with baseline volume and increasing finite element analysis-derived 522 rupture risk. J Vasc Surg. 2016;63:1434-1442.e3. doi: 10.1016/j.jvs.2015.11.051
- 523 27. Berg KE, Ljungcrantz I, Andersson L, Bryngelsson C, Hedblad B, Fredrikson GN, Nilsson 524 J, Björkbacka H. Elevated CD14++CD16- monocytes predict cardiovascular events. Circ 525 Cardiovasc Genet. 2012;5:122-131. doi: 10.1161/CIRCGENETICS.111.960385
- 526 28. Hofmann A, Müglich M, Wolk S, Khorzom Y, Sabarstinski P, Kopaliani I, Egorov D, 527 Horn F, Brunssen C, Giebe S, Hamann B, Deussen A, Morawietz H, Poitz DM, Reeps C. Induction of Heme Oxygenase-1 Is Linked to the Severity of Disease in Human 528 529 Abdominal Aneurysm. J Am Heart Assoc. 2021;10:e022747. Aortic 530 10.1161/JAHA.121.022747
- 531 29. Koole D, Zandvoort HJA, Schoneveld A, Vink A, Vos JA, van den Hoogen LL, Vries J-532 PPM de, Pasterkamp G, Moll FL, van Herwaarden JA. Intraluminal abdominal aortic 533 aneurysm thrombus is associated with disruption of wall integrity. J Vasc Surg. 534 2013;57:77–83. doi: 10.1016/j.jvs.2012.07.003
- 535 30. Cameron SJ, Russell HM, Owens AP. Antithrombotic therapy in abdominal aortic 536 aneurysm: beneficial or detrimental? Blood. 2018;132:2619-2628. doi: 10.1182/blood-2017-08-743237 537
- 538 31. Williams H, Mack C, Baraz R, Marimuthu R, Naralashetty S, Li S, Medbury H. Monocyte 539 Differentiation and Heterogeneity: Inter-Subset and Interindividual Differences. Int J Mol 540 Sci. 2023;24. doi: 10.3390/ijms24108757
- 541 32. Sagan A, Mrowiecki W, Mikolajczyk TP, Urbanski K, Siedlinski M, Nosalski R, Korbut 542 R, Guzik TJ. Local inflammation is associated with aortic thrombus formation in 543 abdominal aortic aneurysms. Relationship to clinical risk factors. Thromb Haemost. 544 2012;108:812-823. doi: 10.1160/TH12-05-0339